Skip to content

A single center, randomized, controlled, opened label study for evaluating Cyclosporin alone or combined with Stanozolol in the treatment of aplastic anemia

A single center, randomized, controlled, opened label study for evaluating Cyclosporin alone or combined with Stanozolol in the treatment of aplastic anemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008738
Enrollment
Unknown
Registered
2016-06-28
Start date
2016-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aplastic anemia

Interventions

A:Cyclosporin
B:Cyclosporin and Stanozolol

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with Non-severe aplastic anemia do not rely on transfusion; 2. Patients with Severe aplastic anemia or Non-severe aplastic anemia relying on transfusion have no condition treated with HSCT or ATG; 3. Aged between 18 to 65 years old; 4. Have not history of cyclosporin, androgens, HSCT or other immunosuppressants treatment; 5. Sign the informed consent document.

Exclusion criteria

Exclusion criteria: 1. With severe organ dysfunction or diseas, such as heart, lung, kidney,pancreas; 2. WIth active hepatitis, syphilis and HIV; 3. Any cause of abormal liver function, grater than twice the normal in ALT/AST or TBIL; 4. ECOG score >2; 5. Pregnant patients; 6. Congenital hematopoietic failure; 7. Uncontrolled infection.

Design outcomes

Primary

MeasureTime frame
blood routine;bone marrow exmination;blood biochemistry;Cyclosporine blood concentration;

Countries

China

Contacts

Public ContactYingmei Li

The First Affiliated Hospital of Zhengzhou University

yingmeibt@163.com+86 13674999228

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026